Third Harmonic Bio Inc.

Third Harmonic Bio — Investor Presentation (July 2023)

17 slides from Third Harmonic Bio's investor presentation, Jul 25, 2023

  1. Slide 1: Focused on advancing the next wave of medicine for inflammatory diseases

    FOCUSED On advancing the next wave of medicine for inflammatory diseases JULY 2023 ©2023 THIRD HARMONIC BIO Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu

  3. Slide 3: Focused on KIT Inhibition to Treat Mast Cell-Mediated Inflammatory Diseases

    “PIPELINE-IN-A-TARGET” POTENTIAL SELECTIVE ORAL KIT INHIBITORS KIT: A NOVEL, CLINICALLY VALIDATED TARGET LARGE ESTABLISHED MARKETS WITH HIGH UNMET NEED Third Harmonic Bio: Focused on KIT Inhibition to Treat Mast Cell-Mediated Inflammatory Diseases Millions of patients living with severe mast cell-me

  4. Slide 4: Mast Cells are a Fulcrum of Inflammation

    MAST CELL Receptor-binding agonists IgE Complement Neuropeptides Microbial products Cytokines TSLP Chemokines Physical activators Temperature Pressure Cell-cell contact Pre-formed mediators Histamine IL-4, IL-13 TNF, GM-CSF Proteases Serotonin Heparin Newly synthesized mediators Prostaglandins Leuko

  5. Slide 5: KIT is the Master Regulator of Mast Cell Function and Survival

    KIT is the Master Regulator of Mast Cell Function and Survival Intracellular small molecule approach to KIT inhibition offers multiple potential therapeutic advantages KIT Master regulator of mast cell proliferation, migration, activation and survival KIT inhibition drives both mast cell inactivatio

  6. Slide 6: THB001 Clinical results from first generation oral KIT inhibitor

    THB001 Clinical results from first generation oral KIT inhibitor

  7. Slide 7: First-Generation Product Candidate: THB001

    First-Generation Product Candidate: THB001 Early results support the potential of oral KIT inhibition and inform next-gen development THB001 demonstrated high potency and selectivity for KIT à mast cell depletion and disease model efficacy in multiple nonclinical studies Phase 1a 14-day healthy volu

  8. Slide 8: THB001 Discontinued Phase 1b Chronic Inducible Urticaria Study Overview

    THB001 Discontinued Phase 1b Chronic Inducible Urticaria1 Study Overview Dose escalation study designed to interrogate potential for therapeutic index optimization Design and Objectives 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks Pharmacokinetics and serum tryptase levels Mean reduction in c

  9. Slide 9: THB001 in Phase 1b CINDU Study Safety Summary

    11 1000 THB001 in Phase 1b CINDU Study Safety Summary No serious or severe adverse events (AEs) Two moderate AEs of transaminitis which resolved at weeks 17 and 25 of follow-up All other AEs were mild Overall profile consistent with on-target effects of KIT inhibition observed in the Phase 1a study

  10. Slide 10: THB001 Generated Responses at Lowest Planned Dose in Phase 1b Study

    THB001 Generated Responses at Lowest Planned Dose in Phase 1b Study 4 of 5 subjects reached partial (n=2) or complete (n=2) Critical Temperature Threshold responses Rapid tryptase reduction: -83% mean change from baseline by week 1 largely consistent with Phase 1a results Strong correlation between

  11. Slide 11: Understanding Hepatic Effects of THB001

    Understanding Hepatic Effects of THB001 Generating mechanistic understanding allows for differentiation of next-generation candidate Conducting studies characterizing liver metabolism and phenotypic effects of THB001 Employing a comprehensive approach: Assessing evidence for off-target biology liabi

  12. Slide 12: THB001 Shows Evidence for Formation of a Toxic Reactive Metabolite

    THB001 Shows Evidence for Formation of a Toxic Reactive Metabolite Three findings from mechanistic studies provide potential basis for observed transaminitis Studies identify major metabolite in human plasma which is formed via a reactive intermediate Metabolite present at higher levels in human pla

  13. Slide 13: THB335 Next generation oral KIT inhibitor

    THB335 Next generation oral KIT inhibitor

  14. Slide 14: THB335 Potent and Selective Small Molecule KIT Inhibitor

    THB335 Potent and Selective Small Molecule KIT Inhibitor Maintained Kinase Inhibition Profile to THB001 but Lacking Evidence for Reactive Metabolite Formation THB001 THB335 KIT IC50 23 nM 9.5 nM PDGFRa Selectivity >100-fold >100-fold CSF1R Selectivity 65-fold >100-fold Off-target cell viability No e

  15. Slide 15: THB335 Demonstrates Favorable Nonclinical Profile

    Potent mast cell depletion across relevant tissue types Favorable nonclinical pharmacokinetic profile, including high oral bioavailability, metabolic stability ​and long circulating half-life Improved solubility and lipophilicity compared to THB001 No liver toxicity signal observed at high multiples

  16. Slide 16: Third Harmonic Bio Next Steps

    Third Harmonic Bio Next Steps Advancing THB355 back toward the clinic with a longer-term view toward franchise expansion THB335 U.S. IND filing and clinical trial initiation anticipated in 1H 2024 Targeting chronic spontaneous urticaria as initial clinical indication Planned expansion into additiona

  17. Slide 17: Advancing the next wave of medicine for inflammatory diseases

    ADVANCING the next wave of medicine for inflammatory diseases

Third Harmonic Bio — Investor Presentation (July 2023) on 6ix